| Name | Title | Contact Details |
|---|
Cerevance is advancing a promising pipeline of new treatments for central nervous system diseases.
Venture Technology Group is a Farmington Hls, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Strategyx is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.